The emerging class of GLP-1 receptor agonist and GIP co-agonist medications, like tirzepatide, semaglutide, and the recently introduced retatrutide, provide promising advances in diabetes control. https://tirzepatide273884.bloggin-ads.com/66949397/retatrutide-one-comparative-examination